Thrombopoietin gene therapy - Bioenvision

Drug Profile

Thrombopoietin gene therapy - Bioenvision

Alternative Names: TPO gene therapy

Latest Information Update: 16 Mar 2007

Price : $50

At a glance

  • Originator Bioenvision
  • Class
  • Mechanism of Action Thrombopoietin stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Suspended Thrombocytopenia

Most Recent Events

  • 30 Jun 2006 Suspended - Phase-I for Thrombocytopenia in USA (Parenteral)
  • 29 Oct 2003 Phase-I clinical trials in Thrombocytopenia in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top